Navicare Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-12-2024
- Paid Up Capital ₹ 0.10 M
as on 20-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 101.79%
(FY 2022)
- Profit -46.88%
(FY 2022)
- Ebitda -183.91%
(FY 2022)
- Net Worth 4.74%
(FY 2022)
- Total Assets 73.85%
(FY 2022)
About Navicare Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Navin Sexena and Kunal Saxena serve as directors at the Company.
- CIN/LLPIN
U24110MH2011PTC216977
- Company No.
216977
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 May 2011
- Date of AGM
15 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Navicare Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navin Sexena  | Director | 03-May-2011 | Current |
| Kunal Saxena | Director | 19-Apr-2013 | Current |
Financial of Navicare Pharma.
Navicare Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 101.79% increase. The company also saw a substantial fall in profitability, with a 46.88% decrease in profit. The company's net worth moved up by a moderate rise of 4.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Navicare Pharma?
In 2021, Navicare Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Quantys Clinical Private LimitedActive 10 years 4 monthsNavin Sexena and Kunal Saxena are mutual person
Navin Saxena Research And Technology Private LimitedActive 30 years 28 daysNavin Sexena and Kunal Saxena are mutual person
Rusan Health Care Private LimitedActive 25 years 1 monthNavin Sexena and Kunal Saxena are mutual person
- Tuscany Holdings Private LimitedActive 30 years 2 months
Navin Sexena and Kunal Saxena are mutual person
Euromed International Private LimitedActive 26 years 10 monthsNavin Sexena and Kunal Saxena are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Navicare Pharma?
Unlock and access historical data on people associated with Navicare Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Navicare Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Navicare Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
